Latest news with #ALXN1840
Yahoo
10 hours ago
- Business
- Yahoo
Chardan Initiates Coverage of Monopar Therapeutics (MNPR) Stock, Gives Buy
Monopar Therapeutics Inc. (NASDAQ:MNPR) is one of the 10 Unstoppable Stocks to Buy According to Hedge Funds. On June 23, Chardan analyst Keay Nakae began coverage of the company's stock with a 'Buy' rating and a price objective of $60, as reported by The Fly. The firm cited potential in its late-stage Wilson disease treatment as well as an early-stage radiopharmaceutical pipeline for the rating. In the research note, the analyst mentioned that the company's co-founder and Chief Executive Officer has a long history with the development of ALXN1840. Close-up of a scientist using a microscope to study a sample, as part of a research project related to cancer prevention. On May 7, 2025, Monopar Therapeutics Inc. (NASDAQ:MNPR) presented long-term efficacy and safety data for ALXN1840 (tiomolybdate choline). The data supported ALXN1840 as a potential treatment for Wilson disease. Pooled results from 3 clinical trials (n=255) exhibited sustained clinical benefits over a median treatment duration of 2.63 years. Monopar Therapeutics Inc. (NASDAQ:MNPR), in collaboration with Excel Diagnostics and Nuclear Oncology Center (EDNOC), announced that the physician-sponsored Expanded Access Program (EAP) for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu has received authorization to proceed from the US FDA. While we acknowledge the potential of MNPR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MNPR and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None.
Yahoo
30-04-2025
- Business
- Yahoo
Why Monopar Therapeutics Inc. (MNPR) is Surging in 2025
We recently published a list of . In this article, we are going to take a look at where Monopar Therapeutics Inc. (NASDAQ:MNPR) stands against other healthcare stocks that are surging in 2025. After lagging behind the broader market in 2024, many healthcare stocks are making a comeback this year. Healthcare spending has been continuously soaring and is projected to do so in the coming years due to demographic tailwinds. The industry now accounts for a fifth of the U.S. economy, and it's a good idea to have exposure to it. Most executives now hold a favorable view of the industry's prospects, a notable increase from 52% just a year ago. Moreover, it's an industry that is more insulated from tariffs and macro risks. Of course, the top gainers here are not defensive healthcare stocks, but it's still worth looking into the winners here if you are chasing potential multibaggers. Even during bear markets, there are pockets of the market that perform exceptionally well. For example, I identified in another article. For this article, I screened the best-performing healthcare stocks year-to-date. I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). Close-up of a scientist using a microscope to study a sample, as part of a research project related to cancer prevention. Number of Hedge Fund Holders In Q4 2024: 5 Monopar Therapeutics Inc. (NASDAQ:MNPR) is a clinical-stage biopharmaceutical company developing novel radiopharmaceuticals for oncology and a late-stage treatment for Wilson disease called ALXN1840. The stock's strong move in 2025 has been propelled by a series of material events, starting with the in-licensing of ALXN1840 from Alexion, AstraZeneca Rare Disease in October 2024. This deal included a $4 million upfront payment, equity issuance, and future milestone and royalty payments, giving Monopar Therapeutics Inc. (NASDAQ:MNPR) exclusive global rights to a Phase 3-ready asset that met its primary endpoint for Wilson disease. In the fourth quarter of 2024 and into early 2025, Monopar Therapeutics Inc. (NASDAQ:MNPR) strengthened its financial position by raising over $55 million through public offerings and private placements, with a notable $19.2 million offering priced at $16.25 per share in March 2025. The company also initiated two first-in-human Phase 1 clinical trials for its radiopharmaceutical pipeline targeting advanced cancers, and announced plans to submit a New Drug Application for ALXN1840 in early 2026. These developments, particularly the ALXN1840 licensing and the capital raises, led to substantial upward moves in the stock price. The consensus price target of $55.33 implies 29.56% upside. Monopar Therapeutics Inc. (NASDAQ:MNPR) stock is up 94.14% year-to-date. Overall, MNPR ranks 13th on our list of healthcare stocks that are surging in 2025. While we acknowledge the potential of MNPR as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than MNPR but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
